Are pro-regenerative therapies the future of osteoarthritis disease modification?
- PMID: 37196977
- DOI: 10.1016/j.joca.2023.05.003
Are pro-regenerative therapies the future of osteoarthritis disease modification?
Conflict of interest statement
Conflicts of interest TLV has received research funding to support the STEpUP OA Consortium from UCB, Galapagos, Biosplice, Novartis, Fidia, and Pfizer. PGC has performed speakers bureaus or consultancies for AbbVie, AstraZeneca, Biosplice, BMS, Eli Lilly, Galapagos, Genascence, GSK, Janssen, Merck, Moebius Medical, Novartis, Pfizer, Regeneron, Stryker, and UCB.
Comment in
-
Towards disease modification in osteoarthritis.Osteoarthritis Cartilage. 2023 Sep;31(9):1154-1155. doi: 10.1016/j.joca.2023.05.002. Epub 2023 May 16. Osteoarthritis Cartilage. 2023. PMID: 37196976
Comment on
-
Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial.Nat Med. 2022 Dec;28(12):2633-2645. doi: 10.1038/s41591-022-02059-9. Epub 2022 Dec 1. Nat Med. 2022. PMID: 36456835 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical